Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug 31:14:1241734.
doi: 10.3389/fendo.2023.1241734. eCollection 2023.

Controlled attenuation parameters to assess liver steatosis in obese patients with polycystic ovary syndrome

Dongxu Wang  1 , Nan Nan  1 , Hao Bing  1 , Bing He  2
Affiliations

Controlled attenuation parameters to assess liver steatosis in obese patients with polycystic ovary syndrome

Dongxu Wang et al. Front Endocrinol (Lausanne). .

Abstract

Objectives: This study was performed to investigate the changes and influencing factors of liver controlled attenuation parameter (CAP) in obese patients with polycystic ovary syndrome (PCOS), and to determine the prevalence and risk factors of nonalcoholic fatty liver disease (NAFLD) in PCOS patients with obesity.

Methods: Forty-one PCOS patients with obesity and twenty age- and body mass index (BMI)-matched control women without PCOS were enrolled in this study. General data, body composition, biochemical parameters, sex hormones, and liver CAP in the two groups were collected and compared. Liver CAP was measured using transient elastography.

Results: NAFLD was more common in the Obese PCOS group than in the control group (75.61% vs. 45.00%, P=0.018). Compared to the control group, the obese PCOS group showed apparent increases in alanine transaminase (ALT), aspartate transaminase (AST), CAP, triglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), totle testosterone (TT), free androgen index (FAI), fasting insulin (FIns), and homeostasis model assessment-insulin resistance (HOMA-IR), along with lower high-density lipoprotein cholesterol (HDL-C) and sex hormone binding globulin (SHBG) levels. In addition, as shown by Spearman analysis, liver CAP in PCOS patients with obesity had a positive correlation with ALT, AST, TG, TT, FAI, FIns, and HOMA-IR, and a negative correlation with SHBG. Logistic regression analysis showed that TG, TT, FIns, and HOMA-IR were risk factors for NAFLD, while TT was an independent risk factor for NAFLD in PCOS patients with obesity.

Conclusion: PCOS patients with obesity had a significantly higher prevalence of NAFLD. Furthermore, in PCOS patients with obesity, liver CAP was associated with disorders of lipid metabolism, insulin resistance, and hyperandrogenemia, with elevated testosterone levels being an independent risk factor for NAFLD in PCOS patients with obesity.

Keywords: controlled attenuation parameter; hyperandrogenemia; non-alcoholic fatty liver disease; polycystic ovary syndrome; testosterone.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Similar articles

See all similar articles

Cited by

References

    1. Deswal R, Narwal V, Dang A, Pundir CS. The prevalence of polycystic ovary syndrome: A brief systematic review. J Hum Reprod Sci (2020) 13(4):261–71. doi: 10.4103/jhrs.JHRS_95_18 - DOI - PMC - PubMed
    1. Li R, Zhang Q, Yang D, Li S, Lu S, Wu X, et al. . Prevalence of polycystic ovary syndrome in women in China: a large community-based study. Hum Reprod (2013) 28(9):2562–9. doi: 10.1093/humrep/det262 - DOI - PubMed
    1. Paschou SA, Polyzos SA, Anagnostis P, Goulis DG, Kanaka-Gantenbein C, Lambrinoudaki I, et al. . Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. Endocrine (2020) 67(1):1–8. doi: 10.1007/s12020-019-02085-7 - DOI - PubMed
    1. Barber TM, Franks S. Obesity and polycystic ovary syndrome. Clin Endocrinol (Oxf) (2021) 95(4):531–41. doi: 10.1111/cen.14421 - DOI - PubMed
    1. Wu J, Yao XY, Shi RX, Liu SF, Wang XY. A potential link between polycystic ovary syndrome and non-alcoholic fatty liver disease: an update meta-analysis. Reprod Health (2018) 15(1):77. doi: 10.1186/s12978-018-0519-2 - DOI - PMC - PubMed

Publication types